Company of the Week: Kura Oncology

Company of the Week: Kura Oncology

On 9 November 2026 Kura Oncology borrowed $50M from Oberland Capital under a facility of up to $275M and sold Oberland shares at $7.27. The loan comes with a royalty on American sales of KOMZIFTI that starts in October 2028 and stops at 20 percent of the principal drawn. Kura already shares American profits with Kyowa Kirin and collects a royalty from Kyowa Kirin on sales outside America.

On 9 November 2026 Kura Oncology signed three agreements with affiliates of Oberland Capital: a loan agreement, a royalty participation agreement and a share purchase agreement. The loan provides up to $275M in five tranches, of which $50M was drawn at closing. Kura used part of it to repay its $10.0M term loan from Hercules Capital. Oberland's affiliate TPC bought 687,758 shares at $7.27, for about $5.0M.

The royalty is the part of the package that runs on sales. Kura will pay quarterly a share of American net sales of ziftomenib, sold as KOMZIFTI, from 1 October 2028. The rate is low single-digit on the first $250M of annual sales, zero between $250M and $1B, and less than 1.5 percent above $1B. Payments stop when they reach 20 percent of the principal funded. If they have not reached it by 9 November 2036, Kura pays the balance.

The next day Kura reported third-quarter KOMZIFTI net product revenue of $13.9M, in its third full quarter on the market, and $492.1M of cash, cash equivalents and short-term investments. In the quarter to 30 September it had sold shares through its at-the-market facility at an average of $12.64.


At a Glance

Item Detail
Company Kura Oncology, Inc., San Diego. Listed on Nasdaq (KURA)
Marketed product KOMZIFTI (ziftomenib), a once-daily oral menin inhibitor approved by the FDA on 13 November 2025 for adults with relapsed or refractory NPM1-mutated acute myeloid leukaemia (AML)
Product revenue, third quarter 2026 $13.9M, up from $9.1M in the second quarter and $5.8M in the first
Product revenue, nine months $28.8M
Net loss, nine months $211.9M
Cash, cash equivalents and short-term investments $492.1M at 30 September 2026, against $667.2M at 31 December 2025
Partner Kyowa Kirin. American profits and losses shared equally; Kyowa Kirin sells outside America and pays Kura tiered double-digit royalties
Kyowa Kirin payments received $595.8M by 30 September 2026, of which $570.0M upfront and milestones
Kyowa Kirin payments outstanding Up to $693.0M of milestones in the current field, $228.0M more on a solid-tumour option, and $180.0M expected in the near term
New financing Oberland Capital: up to $275M of term loans, $50M drawn, SOFR plus 3.20 percent with a floor of 6.95 percent and a cap of 8.95 percent, maturing 9 November 2033
Royalty to Oberland Tiered on American KOMZIFTI net sales from 1 October 2028, capped at 20 percent of principal funded
Pipeline Ziftomenib in frontline AML (Phase 3 KOMET-017, topline in 2028); darlifarnib, a farnesyl transferase inhibitor, with a registrational study planned for the first half of 2027
Royalty posture Royalty holder from Kyowa Kirin outside America; royalty payer to Oberland and, under its licence, to the University of Michigan

A Note on Scope

The Oberland loan agreement, royalty participation agreement and purchase agreement had not been filed at the research date. Kura says it will file them with its annual report for 2026. Terms in this profile come from Part II, Item 5 of the quarterly report for the period to 30 September 2026, the results release of 10 November and the call of the same day. The royalty rates are given only as ranges, and the prepayment and end-of-term charges are not quantified.

The Kyowa Kirin licence was filed in redacted form as an exhibit to the annual report for 2024. Royalty rates, tier breakpoints and milestone amounts are redacted. Calculations in this profile are the author's and state their assumptions where they appear.


Three Claims on One Product

The claims on KOMZIFTI sales after 9 November 2026, by territory

Ziftomenib came from the University of Michigan, which licensed it to Kura with milestone and royalty obligations whose terms Kura does not disclose. Kura took it through registrational trials alone, and in November 2022 signed a term loan facility of up to $125.0M with Hercules Capital, of which it drew $10.0M.

The Kyowa Kirin agreement of 20 November 2024 split the drug by territory. Kura records American sales, manufactures the drug and leads American development and commercial strategy. The two companies share American profits and losses equally.

Outside America, Kyowa Kirin leads development and commercialisation, records the sales and pays Kura royalties. Kyowa Kirin announced an upfront of about $330M and up to about $1.2B of development, approval and sales milestones, and told its investors that it would pay Kura double-digit royalties on sales outside America.

By the end of 2025 Kura had earned $240.0M of development milestones, $195M of them paid in the fourth quarter. By 30 September 2026 it had received $595.8M in all: $570.0M of upfront and milestone payments and $25.8M of profit, loss and expense sharing.

Up to $693.0M of milestones remain in the current field, and $228.0M more if Kyowa Kirin exercises its option on solid tumours.

The licence sets the royalty term country by country. It runs to the latest of the last valid patent claim, regulatory exclusivity, and ten years from first commercial sale in the country, with reductions after the last claim expires, on generic competition and for royalties Kyowa Kirin pays to third parties. The reductions have a floor. All percentages are redacted.

The FDA approved KOMZIFTI on 13 November 2025. Kura recorded $2.1M of net product revenue from first sale on 21 November to the end of the year. In April 2026 Kyowa Kirin dosed the first patient in a Japanese registration-directed Phase 2 trial and said it would file in Japan when the trial ends. No sale outside America has been reported.


The Oberland Package

Tranches of the Oberland loan, the royalty tiers on American net sales, and the cap by amount drawn

The loan has five tranches. Kura drew $50.0M at closing. It may draw $50.0M and $25.0M more at its option by 31 December 2027. A fourth tranche of $50.0M becomes available through 2028 on positive Phase 3 data and is mandatory once available, unless the second tranche has already been drawn. A fifth, of up to $100.0M, is uncommitted.

Interest is three-month SOFR plus 3.20 percent, with a floor of 6.95 percent and a cap of 8.95 percent. For the first twelve quarters after each advance, half the interest is added to principal. All principal falls due on 9 November 2033, with no amortisation.

The loan is secured on substantially all of Kura's assets, including its intellectual property. Kura must repay on a change of control and may prepay only in full, with a prepayment charge and an end-of-term charge. Neither charge is quantified in the quarterly report.

The royalty participation agreement covers American net sales of ziftomenib and certain related products. The rates are tied to the original principal funded, so the percentage rises as Kura draws more. The cap is 20 percent of principal funded, including original issue discount and excluding interest added to principal. On $50M drawn the cap is $10M, and on the full $275M it would be $55M.

The agreement starts on 1 October 2028 and ends at the earliest of 9 November 2036, the date payments reach the cap, or payment of the repurchase price. The repurchase price is the cap less royalties already paid. Kura may pay it at any time, and doing so ends further loan advances.

Oberland may require it on a change of control other than a qualified acquisition, or during an event of default. If the term ends on the outside date, Kura pays the balance then. Repaying the loans does not end the royalty.

Kura's chief executive, Troy Wilson, said on the call that the company had tapped its at-the-market facility for a small amount ahead of its FDA alignment on darlifarnib, and that the Oberland deal created optionality now that Kura had two programmes.

The purchase agreement adds $5.0M of shares at the fourth tranche, at the 30-business-day average price, and an option for Oberland's affiliates to buy up to $15.0M more at the same reference.

The royalty and the loan cover different periods. On the initial $50M, the cap equals 20 percent of principal regardless of sales, because any shortfall at the outside date is paid in cash. Sales decide only when it is paid. If the low single-digit rate were 3 percent, $250M of American net sales in a year would pay $7.5M, and the $10M cap would be reached about 16 months after the royalty starts, in early 2030.

At the third-quarter run rate multiplied by four, $55.7M a year, the same rate would reach the cap in about six years, in late 2034. These figures are the author's and assume a rate the filing does not give.


What Kura Collects and What It Pays

KOMZIFTI and Revuforj revenue by quarter, and Kyowa Kirin payments received and outstanding

Kura recorded $13.9M of product revenue and $8.9M of collaboration revenue in the third quarter, against operating expenses of $97.5M. Collaboration revenue is a non-cash item.

Kura recognises the Kyowa Kirin consideration as it performs, and its contract liabilities stood at $443.9M at 30 September, including $275.3M of constrained commercialisation and profit-sharing consideration. The accumulated deficit was $1.4B.

Approximately 150 patients started KOMZIFTI in the quarter, and 170 accounts had prescribed it. Kura says it holds a majority of new patient starts among menin inhibitors in relapsed or refractory NPM1-mutated AML.

Syndax's Revuforj, also sold in KMT2A-rearranged leukaemia and approved in NPM1-mutated disease on 24 October 2025 and earlier in KMT2A-rearranged leukaemia, recorded $60.7M of net revenue in the same quarter, of which Syndax put more than 35 percent in NPM1-mutated disease.

The Kyowa Kirin licence counts a voucher sale as American revenue. Shared Commercial Revenue is defined as American net sales plus the net proceeds of any priority review voucher Kura sells, and royalties Kura owes under the Michigan licence and a licence from Memorial Sloan Kettering are shared commercial costs.

Kura's filings do not say whether the Oberland royalty is a shared cost. If it is not, Kura alone bears a royalty calculated on sales whose profit it splits.

In September Kura spun out its diabetes programme as Caspian Therapeutics, with $50M led by BVF Partners and including Eli Lilly. Kura contributed KO-7246, a menin inhibitor, and retains about half of Caspian on a fully diluted basis.

Kura's shares fell 12 percent on 4 November to about $8.69. The Oberland shares were priced at $7.27 five days later. At that price, the 91,878,694 shares outstanding on 6 November come to about $668M, against $492.1M of cash and investments at 30 September.


What the Filings Do Not Yet Say

The royalty participation agreement gives its rates as low single-digit, zero and less than 1.5 percent, and ties them to principal funded. The filing does not give the formula. Whether the rate on the first $250M rises in proportion to principal, or steps up by tranche, will decide how fast the cap is reached as Kura draws more.

The text will also show whether the 20 percent cap includes the original issue discount on later tranches and how a qualified acquisition is defined.

The prepayment charge and end-of-term charge on the loan are not quantified. Together with the coupon, the interest added to principal and the royalty, they make up Oberland's return. On the initial $50M, the royalty alone adds a fixed $10M payable by 2036.

The Kyowa Kirin licence does not say, in its unredacted text, whether the Oberland royalty can be charged to the American profit share. The financing royalty was signed two years after the licence, which lists the Michigan and Memorial Sloan Kettering royalties among shared commercial costs.

The annual report for 2026 should show how Kura accounts for the royalty and whether Kyowa Kirin bears half of it.

The quarterly report does not identify the triggers for the $180.0M of near-term Kyowa Kirin milestones Kura counts on. It also gives no outside-America sales, because none have been reported. The royalty Kyowa Kirin pays on such sales, when they begin, sits outside the Oberland participation, which covers American sales only.


Financial Profile

Item Amount Source and date
Product revenue, third quarter $13.9M Results release, 30 September 2026
Product revenue, nine months $28.8M same
Collaboration revenue, nine months $33.2M, against $50.1M same
Research and development, nine months $194.0M same
Selling, general and administrative, nine months $93.6M same
Net loss, third quarter $70.2M, against $74.1M same
Net loss, nine months $211.9M same
Cash, cash equivalents and short-term investments $492.1M same
Contract liabilities, Kyowa Kirin $443.9M, of which $63.5M current Quarterly report, 30 September 2026
Kyowa Kirin payments received $595.8M same
At-the-market sales, 2026 2,563,568 shares at $12.64, $31.5M net same
Hercules loan repaid $10.0M principal, about $11.6M with charges and interest same, 9 November 2026
Oberland loan drawn $50.0M of up to $275.0M same
Oberland equity 687,758 shares at $7.27, about $5.0M same
Shares outstanding 91,878,694 same, 6 November 2026
Development milestones earned to end-2025 $240.0M Annual report, 31 December 2025
Caspian stake About 50 percent, fully diluted Caspian launch, September 2026

Blue Team

  • KOMZIFTI revenue rose from $5.8M to $9.1M to $13.9M over the first three quarters of 2026
  • Kura has received $595.8M from Kyowa Kirin and expects $180.0M more in near-term milestones
  • The Oberland royalty is capped at 20 percent of principal drawn, starts in October 2028, and pays nothing on annual American sales between $250M and $1B
  • The loan has no amortisation, and half the interest is added to principal for three years after each advance
  • Kura expects its resources to fund operations beyond topline KOMET-017 results in 2028
  • Kyowa Kirin's royalties on sales outside America stay with Kura and are outside the Oberland participation
  • Kura retains about half of Caspian, financed by others

Red Team

  • None of the three Oberland agreements had been filed at the research date, and the royalty formula, prepayment charge and end-of-term charge are unpublished
  • The royalty cap is payable in cash at the outside date whatever the level of sales
  • The loan is secured on substantially all assets, including intellectual property, and must be repaid on a change of control
  • Revuforj recorded $60.7M in the third quarter across its indications
  • Kura lost $211.9M in nine months on $28.8M of product revenue
  • The Oberland shares were priced at $7.27, against an average of $12.64 for at-the-market sales earlier in the year
  • Whether Kyowa Kirin shares the Oberland royalty under the profit split is not disclosed

Implications for the Pharmaceutical Royalty and Biotech Capital Markets

Oberland's package is a loan with a royalty attached, priced so that the royalty works as a deferred fee. The cap is fixed at 20 percent of principal and is paid in full by 2036 whatever the sales, so the royalty changes the timing of Oberland's return more than its size.

The zero band between $250M and $1B means Oberland's royalty does not grow with KOMZIFTI's success in the middle of the range, and resumes at under 1.5 percent only if American sales pass $1B.

A royalty on sales that a licensor shares with a partner raises a question that a royalty on wholly owned sales does not. Kura records all American sales and owes the royalty on them, while half the American profit belongs to Kyowa Kirin.

Where the financing royalty falls in the profit split decides whether Kura bears its full cost or half of it.

The Rhythm profile in this series described a revenue interest being loosened beside a new loan. At Kura the royalty came with the loan, from the same lender, under a cap that turns most of the variable claim into a fixed amount.

The Abbisko profile described a licensor collecting a royalty from a partner abroad. Kura collects one from Kyowa Kirin and, from October 2028, pays one to Oberland, on different territories of the same drug.


Recent Developments

  • Kura reports third-quarter results, with KOMZIFTI net product revenue of $13.9M, on 10 November 2026, and amends its at-the-market sales agreement the same day
  • Kura signs the Oberland loan, royalty and share purchase agreements and repays Hercules on 9 November 2026
  • Kura's shares fall 12 percent to about $8.69 on 4 November 2026, the day Kura and Kyowa Kirin announced their ASH presentations
  • Kura and Kyowa Kirin announce eight abstracts for ASH 2026, including first data with FLT3 inhibitors, on 4 November 2026
  • Kura launches Caspian Therapeutics with $50M led by BVF Partners on 9 September 2026
  • Kyowa Kirin doses the first patient in a Japanese registration-directed trial on 24 April 2026
  • No sale or purchase of Kura's royalty from Kyowa Kirin has been identified

Financial History

Date Event
Nov 2022 Term loan facility of up to $125.0M with Hercules Capital; $10.0M drawn
20 Nov 2024 Kyowa Kirin collaboration: about $330M upfront, up to about $1.2B of milestones, equal American profit share, double-digit royalties outside America
Jun 2025 Co-promotion and medical affairs agreement with Kyowa Kirin
4Q 2025 $195M of milestone payments from Kyowa Kirin
13 Nov 2025 FDA approves KOMZIFTI
21 Nov 2025 First commercial sale
Apr 2026 Japanese registration-directed trial begins
2026 2,563,568 shares sold at the market at an average of $12.64
Sep 2026 Caspian Therapeutics launched with $50M
9 Nov 2026 Oberland loan of up to $275M, $50M drawn; royalty participation and share purchase agreements; Hercules repaid
10 Nov 2026 Third-quarter results
31 Dec 2027 Optional second and third tranches expire
2028 KOMET-017 topline results expected; fourth tranche available on positive Phase 3 data through 31 December
1 Oct 2028 Oberland royalty begins
9 Nov 2033 Oberland loan matures
9 Nov 2036 Royalty outside date; unpaid balance of the cap due

Conclusion

Kura sells KOMZIFTI in America and shares the profit with Kyowa Kirin, which will sell it everywhere else and pay Kura a royalty. On 9 November 2026 it added a third party to the American sales. Oberland lent $50M of a possible $275M and took a royalty capped at a fifth of the principal, starting in October 2028 and payable in cash by 2036 if sales have not paid it.

The agreements that set the royalty formula, the prepayment terms and the definition of a qualified acquisition will be filed with the annual report. So will the accounting that shows whether Kyowa Kirin shares the cost. Until then, the terms in the quarterly report of 10 November are the only public account of a royalty that Kura agreed to pay on a product that sold $13.9M in its third full quarter.

All information in this report was accurate as of the research date and is derived from publicly available sources including court opinions, regulatory guidance, academic literature, SEC filings, and financial news reporting. Information may have changed since publication. This content is for informational purposes only and does not constitute investment, legal, or financial advice. The author is not a lawyer or financial adviser.

Subscribe to P05.org

Don’t miss out on the latest issues. Sign up now to get access to the library of members-only issues.
jamie@example.com
Subscribe